Matchpoint Therapeutics is a Watertown, Massachusetts-based biotechnology company pioneering the discovery of precision covalent medicines for autoimmune and inflammatory diseases. Its lead program MPT-062, an oral first-in-class T cell modulator, is being advanced into clinical trials in 2027. The company designs oral small molecules that selectively modulate disease-driving immune cell targets.
1
Round
1
Industry
5
Tags
Oct 7, 2026
Latest raise
Funding activity · 1 round
Oct 7, 2026
$150M
Series B
Led by Nextech Invest
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
